Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT05691231

Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels

A prospective, multicenter post-market clinical follow-up study to evaluate the 10-year long-term safety and effectiveness of the Simplify Disc at two levels in subjects who were enrolled in the IDE study (NCT03123549) and/or post approval study (NCT04980378).

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Cervical Disc Disease Bone Diseases Degenerative Disc Disease Intervertebral Disc Degeneration Musculoskeletal Diseases Spinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject was enrolled in the Simplify Disc IDE (NCT03123549) and/or PAS (NCT04980378) at a participating study site
  • Patient understands the conditions of enrollment and is willing sign an informed consent form to participate in the study

Exclusion criteria

  • Subject had an SSI at the index level during the IDE study (NCT03123549) or the PAS (NCT04980378)
  • Subject was withdrawn or withdrew consent to participate in the IDE study (NCT03123549) or PAS (NCT04980378)

Treatment and study plan

NuVasive Simplify Cervical Artificial Disc

Device

Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.

Primary outcomes

  1. Clinical Composite Success Rate

    Time frame: 10 years

    Individual success is defined as at least a 15 point improvement in Neck Disability Index (NDI) Score at 120 months compared with baseline, maintenance or improvement in neurologic status at 120 months compared with baseline, no additional surgical procedure at the index level within 120 months, and the absence of a serious adverse event classified as implant-associated or implant/surgical procedure-associated within 120 months. A subject must meet each criterion to be considered an overall study success.

    NDI scale is reported in a range from 0 - 100, with 0 consistent with best ability to function and 100 with worst ability to function.

Secondary outcomes

  1. Percentage of subjects meeting the minimal clinically important difference (MCID) for NDI at each annual timepoint

    Time frame: 10 years

    Neck Disability Index; scale is reported in a range from 0-100, with 0 consistent with best ability to function and 100 worst ability to function.

  2. Percentage of subjects meeting MCID for neck and arm pain questionnaire for each of the following pain locations: neck pain, arm pain, left arm pain, right arm pain.

    Time frame: 10 years

    Neck and arm pain questionnaire, scale is reported in a range from 0 to 10, with 0 consistent with no pain and 10 with most pain

  3. Motor status at each annual timepoint compared to baseline

    Time frame: 10 years

    A change of one or more grade levels in muscle strength will be regarded as clinically significant.

  4. Sensory status at each annual timepoint compared to baseline

    Time frame: 10 years

    Sensation will be graded as normal or abnormal (diminished or absent). Any changes from abnormal to normal or absent to diminished will be regarded as clinically significant improvement.

  5. SF-36® Health Survey at each annual timepoint compared to baseline

    Time frame: 10 years

    The SF-36 is a multipurpose survey with 36 questions. The questions were combined, scored and weighted to create mental and physical functioning and overall health-related quality of life. Higher scores indicate better outcomes. Scores range from 0-100.

  6. Dysphagia Handicap Index1 (DHI) at each annual timepoint compared to baseline

    Time frame: 10 years

    DHI is scored from 0-100, with a higher score indicative of a less desirable outcome.

  7. Disc height at each annual timepoint will be compared to baseline

    Time frame: 10 years

    Average disc height is calculated as the simple average of the anterior and posterior disc heights

  8. Adjacent level disc degeneration (ALDD) at each annual timepoint will be compared to baseline

    Time frame: 10 years

    ALDD is graded in accordance with definitions adapted from Kellgren and Lawrence: None; Doutbtful;Minimal;Moderate;Severe

  9. Displacement or migration of the Simplify Disc at each annual timepoint will be compared to the post-op timepoint in the IDE study (NCT03123549)

    Time frame: 10 years

    Device migration assesses significant movement of the implant postoperatively. Changes of >3 mm will be considered significant due to the margin of error in radiographic determination of displacement distances.

  10. Range of motion (ROM) at each annual timepoint compared to baseline

    Time frame: 10 years

    Changes in Global Range of Motion will be calculated by subtracting the range of motion measured at one time point from the baseline range of motion. Change in Global Range of Motion will be reported in units of degrees.

  11. Rate of adverse events attributable to Simplify Disc, or use of additional NuVasive instruments, implants, or technologies at each annual timepoint

    Time frame: 10 years

    Number of adverse events related to Simplify Disc or additional NuVasive products

  12. Patient satisfaction and perceived effect at each annual timepoint

    Time frame: 10 years

    Patient questionnaire assessing satisfaction with treatment and perceived effect of treatment. Success for each satisfaction question will be defined as either a "Definitely True" or "Mostly True" response. Success for the perceived effect question will be defined as either a "Completely Recovered," "Much Improved," or "Slightly Improved" response.

Sponsors and collaborators

Lead sponsor

NuVasive

Industry

Registry information

Important dates

Study start
2023
Primary completion
2029
Study completion
2029
First posted
Jan 19, 2023
Registry last updated
Dec 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.